Monopar to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced that CEO Chandler Robinson, MD, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting January 10, 2022, at 7:00am ET.

Monopar's pipeline includes Validive® for severe oral mucositis in oropharyngeal cancer, camsirubicin for advanced soft tissue sarcoma, and other promising candidates targeting advanced cancers and COVID-19.

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am ET.

Presentation Details:

Date: Monday, January 10, 2022

Time: 7:00am ET

Location: Virtual

https://hcwevents.com/

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive^® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates: 
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

FAQ

When will Monopar Therapeutics present at the H.C. Wainwright BioConnect Conference?

Monopar Therapeutics will present on January 10, 2022, at 7:00am ET.

What is the focus of Monopar Therapeutics?

Monopar Therapeutics focuses on developing therapeutics to extend life and improve the quality of life for cancer patients.

What are the key products in Monopar's pipeline?

Monopar's pipeline includes Validive® for oral mucositis, camsirubicin for soft tissue sarcoma, MNPR-101 for advanced cancers, and MNPR-202 for various cancers.

What is the stock symbol for Monopar Therapeutics?

The stock symbol for Monopar Therapeutics is MNPR.

Where can I watch Monopar's presentation?

Monopar's presentation can be viewed on-demand starting January 10, 2022, via the H.C. Wainwright website.